Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
<i>Background and Objectives</i>: Recently, a randomized controlled trial suggested a potential benefit of baricitinib in patients with diabetes mellitus, preserving β-cell function. However, the clinical evidence currently available is limited. We aimed to assess the potential impact of...
Main Authors: | Cristina Martinez-Molina, Cesar Diaz-Torne, Hye S. Park, Anna Feliu, Silvia Vidal, Hèctor Corominas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/60/3/360 |
Similar Items
-
BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01) -
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
by: M. Tasso, et al.
Published: (2022-12-01) -
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
by: Valentine Deprez, et al.
Published: (2020-10-01) -
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
by: Blanca Hernández-Cruz, et al.
Published: (2023-09-01) -
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
by: Marino Paroli, et al.
Published: (2023-08-01)